%0 Journal Article
%T Estudo da dose excipiente: f¨¢rmaco com avalia£¿£¿o da hiperplasia neointimal por tomografia de coer¨ºncia ¨®ptica e histopatologia em art¨¦rias coron¨¢rias porcinas ap¨®s o emprego do bal£¿o eluidor de sirolimus
%A Takimura
%A Celso Kiyochi
%A Galon
%A Micheli Zanotti
%A Sojitra
%A Prakash
%A Doshi
%A Manish
%A Aiello
%A Vera
%A Gutierrez
%A Paulo Sampaio
%A Carvalho
%A Juliana
%A Ferreira
%A Suzane Kiss
%A Chaves
%A Marcio Jose Figueira
%A Laurindo
%A Francisco Rafael Martins
%A Lemos
%A Pedro Alves
%J Revista Brasileira de Cardiologia Invasiva
%D 2012
%I Scientific Electronic Library Online
%R 10.1590/S2179-83972012000200005
%X background: magic touchtm is a sirolimus based nano carrier balloon. we aimed at finding the excipient:drug ratio with the highest capacity to inhibit neointimal proliferation 28 days after the use of this balloon after bare metal stenting in porcine coronary arteries. methods: fourteen domestic pigs with coronary bare metal stenting followed by dilation (60 seconds) using balloons with an excipient:sirolimus ratio of 1:1, 0.5:1, 0.25:1, 1:0 or a control balloon were evaluated. after 28 days neointimal hyperplasia was assessed by optical coherence tomography and histopathology. results: percent neointimal hyperplasia (%) assessed by optical coherence tomography and histomorphometry was 32.2 and 35.1, 28.1 and 33.4, 17.3 and 20.9, 28.6 and 30.2, and 37.9 and 42.3 in the groups with 0.25:1, 0.5:1, 1:1, 1:0 excipient:sirolimus ratios and control balloon, respectively (p = 0.03 for excipient:sirolimus 1:1 versus control balloon). the neointimal interstrut thickness (mm) was 0.23, 0.30, 0.16, 0.24 and 0.30 in the groups with 0.25:1, 0.5:1, 1:1, 1:0 excipient:sirolimus ratios and control balloon, respectively (p < 0.01 for excipient:sirolimus 1:1 versus control balloon). the scores of inflammation, injury and fibrin deposition were low and there was no significant difference among groups. conclusions: there was a stepwise increase in inhibitory efficacy of neointimal proliferation as the excipient concentration increased; the lowest efficacy was observed with the 0.25:1 excipient:sirolimus formulation and the most intensive inhibition was observed with the 1:1 excipient:sirolimus formulation. the 1:1 excipient:sirolimus formulation significantly reduced neointimal proliferation when compared to the control group, with low inflammation and injury scores.
%K angioplasty
%K balloon
%K coronary
%K coronary restenosis
%K stents
%K sirolimus
%K animal experimentation.
%U http://www.scielo.br/scielo.php?script=sci_abstract&pid=S2179-83972012000200005&lng=en&nrm=iso&tlng=en